Veterans groups urge VA, Congress to prepare for FDA-approved psychedelics for mental health treatment November 19, 2026 - Stars and Stripes
WASHINGTON — The nation’s largest advocacy groups for veterans are urging lawmakers to accelerate clinical research into psychedelic-assisted therapy and remove barriers to access for treatments that prove safe and effective.
The Veterans of Foreign Wars, Special Forces Foundation and Disabled American Veterans provided testimony at a House Veterans Affairs’ Subcommittee on Health hearing Wednesday about multiple studies underway on psychedelic drugs that show promise for treating veterans with PTSD, depression and other mental health conditions.
The 2½-hour hearing featured a panel of doctors, researchers and other experts involved in investigating whether certain psychedelic drugs, such as psilocybin, ibogaine and MDMA, can help veterans whose symptoms do not respond to standard medications.
VA officials testified that the agency is making early preparations to provide therapies that are approved by the Food and Drug Administration for clinical use.
Several psychedelic drugs are moving toward potential approval in 2027 following an April 2026 presidential executive order to fast-track their evaluation, the FDA said.
Naomi Mathis, DAV’s deputy legislative national director, said in written testimony that it is critical for Congress to work with the VA, researchers and veterans to advance these innovative treatment options for veterans suffering from traumatic brain injuries, chronic pain, and the debilitating effects of toxic exposures during military service.
“Veterans deserve access to treatments proven safe and effective through rigorous scientific evaluation,” Mathis testified.
Julia Brownley, of California, the top Democrat on the subcommittee, advised the VA to be ready with a trained workforce and safety protocols in place, in the event that the FDA approves certain psychedelic drugs for use in clinical settings.
“Since 2025, the Trump Administration has taken decisive action to accelerate psychedelic research and eliminate regulatory obstacles that have historically slowed progress,” said Andrew Gradison, a senior adviser to the undersecretary for health.
Michael James, a disabled Army veteran who followed Wednesday’s hearing, said that he received psychedelic-assisted treatment outside the U.S. because the drugs are illegal under federal law.
James said that taking ibogaine under the supervision of a clinician eased the anxiety, migraine headaches and brain fog he experienced from a traumatic brain injury.
“The beauty of ibogaine is it targets the nervous system,” James said. “I could literally feel that it was targeting the spots where I had injuries.”
But James, who has a 100% disability rating for PTSD and his traumatic brain injury injury, said that 18 months after therapy his symptoms returned, but he cannot afford the travel and cost for additional treatment.
Leith J. States, a physician and combat veteran who served in the Navy Medical Corps, emphasized that VA clinical studies must demonstrate both the benefits and risks of different psychedelic drugs to help clinicians and veterans make informed decisions.
“Veterans with coexisting conditions and complex medication histories need deliberate consideration as studies develop,” States said.
The DAV has launched an online platform called MindScapes with information on scientific findings, potential benefits and risks connected to psychedelic-assisted therapies for veterans.
The goal is to provide veterans, policymakers and the public with “credible information” on the treatments, the organization said.
DAV is among groups pointing to the higher suicide rate among former service members, who often are affected by PTSD and other mental health problems from military service.
Veterans kill themselves at about twice the rate as nonveterans, according to the VA Office of Suicide Prevention, which analyzes information from death certificates.
Mathis noted the results of a 2024 Stanford University study that followed 30 veterans with traumatic brain injuries from repeated blast exposures.
Participants received ibogaine for depression, anxiety, and other psychiatric problems. Nearly 90% showed improvements.
“These findings are promising. They underscore why larger, rigorous trials conducted within the veteran population remain essential,” Mathis said.
|